adenine has been researched along with Parkinson Disease in 26 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Congenital hydrocephalus (CH) is caused by genetic mutations, but whether factors impacting human genetic mutations are disease-specific remains elusive." | 2.72 | Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions. ( Hart, C; McKnight, I; Park, IH; Shim, JW, 2021) |
| "At the molecular level, Parkinson's disease share common molecular signatures with most neurodegenerative diseases including the accumulation of misfolded proteins in the brain." | 2.61 | Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. ( Gonzalez, C; Hetz, C; Lopez, N; Martinez, A, 2019) |
| "Neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain." | 2.50 | Prions: generation and spread versus neurotoxicity. ( Halliday, M; Mallucci, GR; Radford, H, 2014) |
| "Baicalein was administrated from 7 to 12 week." | 1.46 | Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy. ( Cao, X; Kuang, L; Lu, Z, 2017) |
| "L-Dopa, the standard therapeutic for Parkinson's disease, is inactivated by the enzyme catechol-O-methyltransferase (COMT)." | 1.37 | Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. ( Borroni, E; Diederich, F; Ehler, A; Ellermann, M; Jakob-Roetne, R; Lerner, C; Paulini, R; Roth, D; Rudolph, MG; Schlatter, D; Schweizer, WB, 2011) |
| "Monogenic forms of Parkinson's disease (PD) provide an opportunity to examine mechanisms underlying phenotypic variation." | 1.34 | Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. ( Athanassiadou, A; Bonifati, V; Di Iorio, G; Golbe, LI; Johnson, WG; Markopoulou, K; Papapetropoulos, S; Spychala, JR; Stenroos, ES; Vance, JM; Watts, RL; Williams, TA, 2007) |
| "All compounds tested reversed the catalepsy induced by haloperidol." | 1.33 | New adenosine A2A receptor antagonists: actions on Parkinson's disease models. ( Cristalli, G; Morelli, M; Pinna, A; Volpini, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Pupyshev, AB | 1 |
| Tenditnik, MV | 1 |
| Ovsyukova, MV | 1 |
| Akopyan, AA | 1 |
| Dubrovina, NI | 1 |
| Tikhonova, MA | 1 |
| McKnight, I | 1 |
| Hart, C | 1 |
| Park, IH | 1 |
| Shim, JW | 1 |
| Kuang, L | 1 |
| Cao, X | 1 |
| Lu, Z | 1 |
| Martinez, A | 1 |
| Lopez, N | 1 |
| Gonzalez, C | 1 |
| Hetz, C | 1 |
| Yang, F | 1 |
| Yang, YP | 1 |
| Mao, CJ | 1 |
| Liu, L | 1 |
| Zheng, HF | 1 |
| Hu, LF | 1 |
| Liu, CF | 1 |
| Piersanti, G | 1 |
| Bartoccini, F | 1 |
| Lucarini, S | 1 |
| Cabri, W | 1 |
| Stasi, MA | 1 |
| Riccioni, T | 1 |
| Borsini, F | 2 |
| Tarzia, G | 1 |
| Minetti, P | 1 |
| Endo, K | 1 |
| Deguchi, K | 1 |
| Matsunaga, H | 1 |
| Tomaya, K | 1 |
| Yamada, K | 1 |
| Halliday, M | 1 |
| Radford, H | 1 |
| Mallucci, GR | 1 |
| Yakhine-Diop, SM | 1 |
| Bravo-San Pedro, JM | 1 |
| Gómez-Sánchez, R | 1 |
| Pizarro-Estrella, E | 1 |
| Rodríguez-Arribas, M | 1 |
| Climent, V | 1 |
| Aiastui, A | 1 |
| López de Munain, A | 1 |
| Fuentes, JM | 1 |
| González-Polo, RA | 1 |
| Zhang, Y | 1 |
| Wu, JY | 1 |
| Weng, LH | 1 |
| Li, XX | 1 |
| Yu, LJ | 1 |
| Xu, Y | 1 |
| Volpini, R | 4 |
| Dal Ben, D | 1 |
| Lambertucci, C | 1 |
| Marucci, G | 2 |
| Mishra, RC | 1 |
| Ramadori, AT | 1 |
| Klotz, KN | 1 |
| Trincavelli, ML | 1 |
| Martini, C | 1 |
| Cristalli, G | 4 |
| Finaurini, S | 1 |
| Buccioni, M | 1 |
| Lammi, C | 1 |
| Kandhavelu, M | 1 |
| Ricciutelli, M | 1 |
| Angeli, P | 1 |
| Commandeur, JN | 1 |
| Pinna, A | 4 |
| Tronci, E | 1 |
| Schintu, N | 1 |
| Simola, N | 1 |
| Pontis, S | 2 |
| Morelli, M | 3 |
| Oses, JP | 1 |
| Batassini, C | 1 |
| Pochmann, D | 1 |
| Böhmer, AE | 1 |
| Vuaden, FC | 1 |
| Silvestrin, RB | 1 |
| Oliveira, A | 1 |
| Bonan, CD | 1 |
| Bogo, MR | 1 |
| Souza, DO | 1 |
| Portela, LV | 1 |
| Sarkis, JJ | 1 |
| Mello e Souza, T | 1 |
| Hassin-Baer, S | 1 |
| Hattori, N | 1 |
| Cohen, OS | 1 |
| Massarwa, M | 1 |
| Israeli-Korn, SD | 1 |
| Inzelberg, R | 1 |
| Ellermann, M | 1 |
| Paulini, R | 1 |
| Jakob-Roetne, R | 1 |
| Lerner, C | 1 |
| Borroni, E | 1 |
| Roth, D | 1 |
| Ehler, A | 1 |
| Schweizer, WB | 1 |
| Schlatter, D | 1 |
| Rudolph, MG | 1 |
| Diederich, F | 1 |
| Jiang, TF | 1 |
| Zhang, YJ | 1 |
| Zhou, HY | 1 |
| Wang, HM | 1 |
| Tian, LP | 1 |
| Liu, J | 1 |
| Ding, JQ | 1 |
| Chen, SD | 1 |
| GOMIRATO, G | 1 |
| HYDEN, H | 1 |
| Golbe, LI | 1 |
| Di Iorio, G | 1 |
| Markopoulou, K | 1 |
| Athanassiadou, A | 1 |
| Papapetropoulos, S | 1 |
| Watts, RL | 1 |
| Vance, JM | 1 |
| Bonifati, V | 1 |
| Williams, TA | 1 |
| Spychala, JR | 1 |
| Stenroos, ES | 1 |
| Johnson, WG | 1 |
| Vilar, R | 1 |
| Coelho, H | 1 |
| Rodrigues, E | 1 |
| Gama, MJ | 1 |
| Rivera, I | 1 |
| Taioli, E | 1 |
| Lechner, MC | 1 |
| Lücking, CB | 1 |
| Kösel, S | 1 |
| Mehraein, P | 1 |
| Graeber, MB | 1 |
| Loeffler, DA | 1 |
| Camp, DM | 1 |
| Juneau, PL | 1 |
| Harel, E | 1 |
| LeWitt, PA | 1 |
| Barbieri, S | 1 |
| Hofele, K | 1 |
| Wiederhold, KH | 1 |
| Probst, A | 1 |
| Mistl, C | 1 |
| Danner, S | 1 |
| Kauffmann, S | 1 |
| Sommer, B | 1 |
| Spooren, W | 1 |
| Tolnay, M | 1 |
| Bilbe, G | 1 |
| van der Putten, H | 1 |
5 reviews available for adenine and Parkinson Disease
| Article | Year |
|---|---|
Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
Topics: Adenine; Alzheimer Disease; Animals; Carrier Proteins; Chromosome Mapping; Chromosomes; Databases, G | 2021 |
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease.
Topics: Adenine; Adrenergic alpha-2 Receptor Agonists; Animals; Disease Models, Animal; Endoplasmic Reticulu | 2019 |
Prions: generation and spread versus neurotoxicity.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; eIF-2 Kinase; Humans; I | 2014 |
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials, Phase I | 2009 |
Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Disease Models, Animal; Humans; Lewy Bo | 2001 |
21 other studies available for adenine and Parkinson Disease
| Article | Year |
|---|---|
Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.
Topics: Adenine; Animals; Autophagy; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Transgenic; MTO | 2021 |
Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy.
Topics: Adenine; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dop | 2017 |
Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein.
Topics: Adenine; alpha-Synuclein; Animals; Autophagy; Cell Survival; Chymotrypsin; Humans; Oligopeptides; Pa | 2013 |
Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Binding, Competitive; CHO Cel | 2013 |
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Antipsychotic Agents; Cat | 2014 |
G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Autophagy; Case-Control Studies; Caspases; Cells, Cultured; Do | 2014 |
Valproic acid protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Humans; | 2017 |
Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Binding Sites; Computer Simulation; Crystallogr | 2009 |
In vitro metabolism studies of new adenosine A 2A receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrom | 2008 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 5'-Nucleotidase; Acid Anhydride Hydrolases; Adenine; Adrenergic Agents; Animals; Corpus Striatum; Di | 2011 |
Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up.
Topics: Adenine; Adult; Age of Onset; Aged; Disability Evaluation; Disease Progression; Family Health; Femal | 2011 |
Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Topics: Adenine; Catalysis; Catalytic Domain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inh | 2011 |
Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.
Topics: Adenine; alpha-Synuclein; Autophagy; Blotting, Western; Cell Line; Cell Survival; Curcumin; Genetic | 2013 |
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park | 1963 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Anim | 2005 |
Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.
Topics: Adenine; Adult; Age of Onset; Aged; Aged, 80 and over; Alleles; alpha-Synuclein; Glutathione Transfe | 2007 |
Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease.
Topics: Adenine; Aged; Aged, 80 and over; Alleles; Cytochrome P-450 CYP2D6; Gene Deletion; Genetic Predispos | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functi | 2007 |
Absence of the mitochondrial A7237T mutation in Parkinson's disease.
Topics: Adenine; Base Sequence; DNA Primers; DNA, Mitochondrial; Electron Transport Complex IV; Frontal Lobe | 1995 |
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
Topics: Adenine; Adenosine; Animals; Disease Models, Animal; Dopamine; Guanine; Guanosine; Hypoxanthine; Neo | 2000 |